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The de novo design of simplified porphyrin-binding helical bundles is a versatile approach for 
the construction of valuable biomolecular tools to both understand and enhance protein functions 
such as electron transfer, oxygen binding and catalysis. However, the methods utilised to design 
such proteins by packing hydrophobic side chains into a buried binding pocket for ligands such 
as heme have typically created highly flexible, molten globule-like structures, which are not 
amenable to structural determination, hindering precise engineering of subsequent designs. 
Here we report the crystal structure of a de novo two-heme binding “maquette” protein, 4D2, 
derived from the previously designed D2 peptide, offering new opportunities for computational 
design and re-engineering. The 4D2 structure was used as a basis to create a range of heme 
binding proteins which retain the architecture and stability of the initial crystal structure. A well-
structured single-heme binding variant was constructed by computational sequence redesign of 
the hydrophobic protein core, assessed by NMR, and utilised for experimental validation of 
computational redox prediction and design. The structure was also extended into a four-heme 
binding helical bundle resembling a molecular wire. Despite a molecular weight of only 24kDa, 
imaging by CryoEM illustrated a remarkable level of detail in this structure, indicating the 
positioning of both the secondary structure and the heme cofactors. The design and 
determination of atomic-level resolution in such de novo proteins is an invaluable resource for 
the continued development of novel and functional protein tools. 
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Introduction. 
Computational, de novo protein design has attained a level of sophistication where atomistic 
precision is almost routine1,2, and there now exist a multitude of examples demonstrating our 
command over these fundamental biomolecular building blocks3,4. Conversely, where 
oxidoreductase cofactors have been successfully incorporated into simplified protein 
scaffolds5,6,7, principally termed maquettes, there are limited examples where high-resolution 
structural information has been successfully obtained8,9,10. This shortfall hinders the downstream 
engineering of these robust and versatile scaffolds to incorporate substrate binding sites, tailor 
active site residues and fine tune cofactor biophysical properties in a predictable manner. 
Ultimately, such fine control of structure will lead to significant improvements in these proteins, 
aiding the expansion of their functional and catalytic repertoire, and enabling, for instance, 
imprinted regio- and stereoselectivity in de novo oxidoreductase enzymes.  
 
Despite the drive toward well-packed, native-like states in de novo proteins, it should be noted 
that certain heme-containing maquettes exhibit catalytic activities comparable to their natural 
counterparts while adopting conformationally dynamic structures more reminiscent of molten 
globules than well-folded native-like states11,12. In these cases, the dynamic nature of the protein 
may in fact enhance catalytic activity by lowering barriers to substrate entry and product exit, 
though the relationship between dynamics and catalysis in these simple proteins currently 
remains unclear11,13,14. Since these activities extend to industrially and biosynthetically valuable 
reactions12, it would be prudent to explore this relationship in greater depth and establish a 
framework of robust, engineerable de novo proteins to address these and other fundamentally 
important questions relating to biologically relevant phenomena, such as electron transfer. 
 
To this end, here we describe the design and construction of single and multi-heme proteins with 
well-defined structures and biophysical properties that can be predictably fine-tuned. Our 
strategy was based on the successful design and characterisation of the D2 peptide by the 
Degrado lab15, which self assembles into a diheme tetrahelical bundle. Following the addition of 
simple loops, we created a single chain variant with nanomolar heme affinity, 4D2, that we were 
able to crystalise, obtaining a high-resolution structure of the heme-bound maquette. This 
structure guided the subsequent computational design of a rigid monoheme maquette, and an 
extended tetraheme maquette. We obtained further structural insight into our designs using NMR 
spectroscopy and cryo-electron microscopy, the latter enabling heme-enhanced visualization of 
our 24 kDa tetraheme maquette which represents the current mass limit of the technique. This 
structural information and our confidence in the fidelity of the design process enabled the 
implementation of Monte Carlo Continuum Electrostatic Calculations16 to produce further 
maquettes with predictably altered redox potentials. Such fine-tuning of a fundamental 
biophysical property of the cofactor is central to heme protein engineering and the future 
construction of efficient oxidoreductases on our own terms. 
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Results. 
Conversion of the D2 peptide to an in vivo expressed single-chain protein. 
For a design process with higher precision than that used in the construction of the earlier 
maquettes, we selected the D2 peptide15 reported by Ghirlanda et al, as a starting point for 
further design. D2 was originally designed by parameterizing the transmembrane cytochrome b 
subunit of the cytochrome bc1 complex, using computational methods to define a sequence that 
would self-assemble into a soluble tetrahelical bundle with overall D2 symmetry in the presence 
of heme. The resulting peptide demonstrated high (but undefined) affinity for two heme Bs within 
the assembly, and relatively well-resolved 2D HSQC NMR spectra were observed in presence 
of the heme B cofactors. Despite these promising observations, no high-resolution structural 
information was obtained. We reasoned that the heme B binding affinity could be improved by 
creating a single chain tetrahelical bundle, potentially preorganising the heme binding sites and 
reducing the entropic cost of complex assembly in the unconnected D2:heme B assembly. Given 
the computational design of the heme binding sites and NMR data, it was also hoped that the 
single chain variant would retain the apparent singular, near-native structure of the original 
assembly.  
 
To achieve this single chain variant of D2, we designed a protein where four copies of the 25-
residue D2 peptide were linked together by three short loops: two TSN loops between helices 
1-2 and 3-4; and one GSVSP sequence at the central loop between helices 2-3. We also 
included a TEV (Tobacco Etch Virus N1A) protease-cleavable hexahistidine tag and V5 epitope 
at the N-terminus to enable purification by metal affinity chromatography and antibody detection 
respectively, resulting in a 112-amino acid four helix bundle after TEV-cleavage. Following 
creation of a synthetic gene and expression in T7 Express (NEB) E. coli from pET151 (Thermo), 
a vibrantly red cell pellet was obtained, indicating in vivo heme B binding (Fig. 1). Whilst 
cytoplasmic expression of the protein with or without supplementation with the heme precursor 
γ-aminolevulinic acid17 can yield significant heme binding, the reliability of cofactor incorporation 
was increased considerably by periplasmic export, facilitated by cloning 4D2 into a modified 
pMal-p4x vector (pSHT) containing a cleavable, N-terminal signal sequence for periplasmic 
export, used previously for the expression of de novo c-type maquettes18. Low heme loaded 
cytoplasmic preparations can be recovered either through titration of hemin into purified protein, 
or through supplementation with excess hemin on cell lysis. Reconstitution of 4D2 with heme B 
results in protein with identical biophysical and spectroscopic properties to periplasmically-
expressed 4D2 or cytoplasmically-expressed 4D2 with a full heme complement. In addition, to 
facilitate heme B binding studies and to assess the biophysical characteristics of the apo-4D2, 
we were able to remove bound heme B using acid:2-butanone extraction, as previously 
described19. 
 
Heme-bound 4D2 exhibits UV/visible spectra typical of proteins binding heme B by bis-histidine 
ligation, with a distinctive Soret peak at 416 nm in the oxidized, ferric state5,20,21. We 
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subsequently used electrospray ionization mass spectrometry (ESI-MS) under aqueous, non-
denaturing conditions22 to confirm the protein mass and further examine heme binding. Under 
these soft ionization conditions, we principally observe the diheme 4D2 complex at the correct 
mass, with only with only a small proportion of monoheme- or apo-4D2 m/z peaks observed 
(Figure 1C). Conversely, the heme groups dissociate under the conditions of MALDI mass 
spectrometry, resulting solely in the detection of apo-4D2. Following titrations of hemin into apo-
4D2, we established tight heme B binding, with an observed dissociation constant (KD) of < 5 
nM, and with no evidence of negative cooperativity. Using circular dichroism, we also observe 
that heme binding dramatically increases the helicity and thermal stability of 4D2; apo-4D2 is 
fully unfolded at 37oC, while diheme 4D2 demonstrates only a small loss in helicity until the start 
of a more cooperative melting event above 80oC (Fig. 2). To determine the heme redox 
potentials, we used optically transparent thin layer (OTTLE) electrochemistry23, observing 
midpoint potentials of -182 mV and -115 mV, and, in notable contrast to the equivalent data 
obtained for diheme D2, there is no evidence of hysteresis in these redox titrations. Also, unlike 
the original D2 peptide complex15, the 2D H1-N15-HSQC spectra of diheme 4D2 exhibited only 
moderate signal dispersion (Supplementary Fig. 1), offering only minimal potential of peak or 
structural assignment by NMR. This could indicate that multiple protein conformations exist and 
possibly interconvert on the NMR timescale, or possibly that there exists another source of 
structural heterogeneity in diheme 4D2. 
 
Crystal Structure of a de novo Heme-Bound Maquette. 
Though the NMR indicated structural heterogeneity, we successfully obtained crystals of the 
diheme 4D2 from 96-well sitting drop screening plates, though crystal formation was slow, 
requiring 4 months for the appearance of the first crystals and 6 months to produce diffraction-
quality crystals. We were able to collect datasets at four wavelengths at the I03 beamline at 
Diamond light source, the fluorescence profile of the two iron atoms of the heme groups 
facilitating experimental phase determination by multi-wavelength anomalous dispersion 
(MAD)24. We subsequently determined the crystal structure to a resolution of 1.9 Å (Fig. 3), 
representing one of the first reported structures of a heme- or porphyrin-binding de novo protein. 
 
The solved crystal structure of 4D2 matches very well to the expected fold, with four helices 
arranged in an ordered coiled coil-like structure and the four histidine residues ligating each of 
the two heme cofactors across opposite helices. The identical helical regions fit the D2 symmetry 
of the original parameterized peptide design15. Each histidine is contacted by a threonine within 
an approximate hydrogen bonding distance, most likely forming the ‘keystone’ hydrogen bonding 
interactions in the original design. While the two shorter TSN loops on one side of helical bundle 
are resolved, the flexible GSVSP loop between helices two and three is not observed in this 
structure, suggesting a relatively disordered region around the adjacent protein termini. 
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Interestingly, there is evidence of disorder in the heme B orientations within the binding pockets, 
with extended density visible in positions 1, 2, 3 and 4 of the tetrapyrrole ring. We attribute this 
to the presence of two binding modes, related to each other by a 180o rotation of the asymmetric 
heme, placing the 2 and 4 vinyl groups in the apparent 1 and 3 methyl positions of the 
corresponding other orientation. This has been observed in other heme B binding proteins, 
including neuroglobin25 and several bacterioferritins26,27, where near equal occupancy of the two 
modes was observed. This may also explain the poor signal dispersion in the NMR; combined 
with the repetitive sequence of the four helices, the four possible combinations of heme 
orientations would certainly lead to significant peak broadening and relatively poor dispersion. 
So, while heterogeneity seems apparent from the NMR data, it may not be due to the global 
conformational dynamics of the protein, and the diheme 4D2 may possess more native like 
structure in solution than was initially presumed. The edge-to-edge distance between the heme 
cofactors is small (2.6 Å) and close to being within Van der Waals contact, facilitating rapid 
electron transfer between the heme groups28. 
 
Expansion and Redesign: Single and Multi-Heme Variants of 4D2. 
Following the successful determination of the 4D2 structure, we reasoned that the scaffold could 
provide a template for further heme protein design, enabling us to access single and multi-heme 
proteins with similar atomistic control. We initially designed a monoheme variant, m4D2, using 
Rosetta29 to remove one of the heme binding sites and repack the vacated binding pocket in the 
protein core. We selected the heme binding site adjacent to the termini and longer GSVSP loop 
for removal, and used a flexible backbone design protocol30 to mutate key positions in the core 
to an abbreviated library of hydrophobic amino acids. To minimize unnecessary and potentially 
destabilizing changes to the protein, we used SOCKET31 to identify key knobs-into-holes 
interactions, and avoided modification of the residues involved in these contacts. In total, we 
selected 11 residues for the redesign process, representing about 10% of the total protein, of 
which, 9 were mutated in the final sequence of m4D2. The flexible backbone protocol we 
employed utilized the Backrub method32 for backbone sampling, applying relatively small 
changes to the structure relative to the initial crystal structure. To achieve this, we adapted a 
Rosetta Script from Pollizi et. al. (2017)33, used for the design of a photoactive porphyrin-binding 
tetrahelical bundle. More aggressive backbone sampling methods such as the FastDesign 
mover30 or alternating rounds of sequence design (FixBB) and FastRelax were also tested 
(Supp. Info.), however although these methods converged to a lower overall Rosetta energy 
score, molecular dynamics simulations of the apo-m4D2 design suggested that these 
approaches caused significant disruption to the overall structure. 
 
Conversely, to facilitate the creation of nanoscale protein wires for long range electron transfer, 
we also designed an extended 4D2 variant, e4D2, capable of binding four heme B’s in a linear 
array. This required duplication of the diheme 4D2 unit, extending the protein along its helical 
axis. To ensure appropriate orientation of the heme-ligating histidine side chains into the core of 
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the protein, we separated equivalent histidine residues by 21 residues to fit approximately to 
three cycles of the helical heptad repeat observed in coiled-coil structures. We built each helix 
by repeating the sequence of the 25-residue 4D2 helix, removing two residues from each 
sequence at the junction between repeats, ensuring the correct histidine orientation. This 
resulted in the 46-residue e4D2 helix, for which we constructed a model using the ISAMBARD34 
design package. We extracted coiled-coiled parameters from the 4D2 crystal structure and used 
them to construct the extended helical structure. Finally, we selected the same set of loops from 
the initial 4D2 design to link the e4D2 helices, and then refined and minimized the model using 
Rosetta. 
 
Heme Binding, Helicity and Redox Potentiometry of m4D2 and e4D2. 
After cloning the mono- and tetraheme m4D2 and e4D2 into the same expression vector as 4D2, 
we cytoplasmically expressed the proteins in E. coli using the same method as for 4D2. Like 
4D2, m4D2 binds heme B in vivo and retains it through purification, resulting in a ferric UV/visible 
spectrum indistinguishable from 4D2 (Fig. 5A) and similarly high heme binding affinity (KD <3 
nM). In contrast, e4D2 does not bind a significant quantity of heme B in vivo under cytoplasmic 
expression, and we instead primarily purify apoprotein; however, apo-e4D2 readily binds 
exogenous heme B in vitro, exhibiting a similar ferric UV/visible spectrum to both 4D2 and m4D2. 
Analysis of heme-loaded e4D2 by size exclusion chromatography revealed the presence of 
aggregated, heme-containing protein, but also a significant quantity of heme-loaded e4D2 
eluting at a volume corresponding well to that of a monomeric 25 kDa protein. We found that the 
yield of monomeric, heme-loaded e4D2 can be improved by adding heme at 37oC, with marked 
suppression of aggregated or misfolded material relative to additions at 4 and 25oC (Figure 6F). 
Once separated, this monomeric, heme-bound e4D2 remains stable for several weeks (at 4oC), 
and further size exclusion chromatography indicated only monomeric e4D2 was present. Given 
the tendency of purified e4D2 to produce misfolded protein on the addition of heme B, 
quantification of the heme binding affinity is challenging; however, competition assays using apo 
horse heart myoglobin35 indicate that binding is tight and likely in the nanomolar range 
(Supplementary Fig. 2). To confirm the heme-binding stoichiometry of m4D2 and e4D2, we 
performed non-denaturing mass spectrometry on the two designs, revealing the intended 1:1 
and 4:1 heme-bound complexes of m4D2 and e4D2 respectively. 
 
We then used electrochemistry to provide an insight into the heme environment of these new 
4D2 variants (Fig. 5). e4D2 exhibits a broadly similar potentiometric titration to 4D2, with similar 
overall midpoint potential. While we initially attempted to fit the data to a Nernst function with 
four single electron redox changes, there were multiple solutions with equal statistical validity 
and potentials ranging from -120 mV to -195 mV. A possible route to disentangle the 
potentiometric data would involve selectively modifying or replacing hemes within e4D2 to 
perturb their individual midpoint potentials, but this is beyond the scope of the present study and 
future work will focus on achieving this selective modulation of heme potential in a chain of the 
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redox cofactors. For simplicity, we instead used a Nernst function representing two single 
electron redox events, and observed a slightly smaller separation between midpoint potentials 
than for 4D2 (-124 and -194 mV for e4D2). This indicates that the hemes are essentially paired 
in redox potential, with the outer and inner hemes experiencing differing electric field 
environments as a result of being in close proximity to one or two other hemes respectively. 
Conversely, m4D2 exhibited a significant positive shift in midpoint potential (Em = -118 mV) 
when compared to 4D2. This is consistent with the expected electric field effects of placing 
hemes in close proximity, as previously demonstrated in earlier iterations of the heme-containing 
maquettes20,36,37. 
 
We subsequently employed circular dichroism spectroscopy to probe m4D2 and e4D2 
secondary structure and thermal stability. We observed a predictably high degree in helicity for 
both the monoheme 4D2 and the tetraheme e4D2, and both exhibit excellent thermal stability 
with no evidence of significant helical unfolding up to 95oC. In contrast to 4D2 and e4D2, apo-
m4D2 also exhibits a relatively high degree of helicity and good thermal stability, with a 
cooperative melt transition starting at approximately 60oC. These observations are consistent 
with our design methodology and that previously implemented by Degrado et al 33; we designed 
m4D2 to contain a well folded core where the second heme binding site was removed, while 
allowing flexibility around the unoccupied, remaining heme site. 
 
NMR analysis of the single cofactor m4D2 2,4-DMDPIX complex. 
Unfortunately, we were unable to obtain diffraction-quality crystals of either holo-m4D2 or e4D2. 
However, NMR spectroscopy demonstrated that the monoheme m4D2, was well-structured, with 
good peak dispersion in the 2D H1N15-HSQC spectrum (Figure 7). Given the observation of 
alternative heme orientations in the crystal structure of 4D2, we reasoned that substitution of 
heme B for a symmetrical variant would eliminate such binding heterogeneity and improve NMR 
signal dispersion. We therefore selected the symmetric heme derivative, iron 2,4-dimethyl-
deuteroporphyrin (DMDPIX) for incorporation38, as it contains methyl groups in all 1-4 porphyrin 
positions. DMDPIX binds to m4D2 with slightly lower affinity than heme B (25 nM vs 3 nM 
respectively), most likely due to the removal of hydrophobic interactions between binding site 
residues and the vinyl groups of heme B. With DMDPIX bound to double isotopically labelled 
m4D2 (13C15N), we were able to obtain 3D NMR spectra that enabled the assignment of >90% 
of backbone and a large proportion of side chain atoms (Supplementary Table 2). While this 
data indicates that m4D2 adopts a singular native-like structure, we were unable to obtain 
sufficient long-range NOE interactions to enable full structural assignment, due to the 
paramagnetic influence of the symmetric heme. Given these data, we obtained a 2D H1N15-
HSQC spectrum of 4D2 with DMDPIX bound and observed a similar improvement in peak 
dispersion relative to heme B-bound 4D2, further highlighting the issue of heme binding site 
heterogeneity. We also obtained 2D NMR spectra of apo-m4D2, demonstrating reasonable peak 
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dispersion which further supports evidence of a well-packed core and relatively 
flexible/disordered heme binding site when vacant.  
 
Structural insights into the 25kDa e4D2 by cryoEM. 
We reasoned that the four heme irons in the tetraheme e4D2 might provide sufficient electron 
density to observe the protein using electron microscopy. To this end, we initially screened 
heme-bound e4D2 by negative stain transmission electron microscopy (TEM) and demonstrated 
evidence of the protein’s extended linear helical structure, with many particles fitting well to the 
approximate dimensions of 7.5 nm x 2 nm described by the constructed model. Given these 
TEM results, we then acquired cryo-electron micrographs of tetraheme e4D2. Initially, we 
collected a dataset of approximately 2000 high quality electron micrographs after optimizing 
grids for thin ice conditions. Whilst the protein is challenging to identify from cryoEM 
micrographs, particularly using auto-picking software, we obtained 2D class averages or 
particles which fit very well to the designed protein specification (Figure 8). These averages 
show remarkable detail for such a small protein, demonstrating four distinct ‘segments’ along 
the helical bundle which correspond to the positions of each heme B in addition to depicting four 
distinct helical structures from a top-view of the molecule through the helical axis. This provides 
the most substantial evidence that the molecule folds to the designed structure, forming an 
extended helical bundle with the four tightly packed heme groups positioned in the core of the 
protein. Preliminary 3D reconstructions of the model demonstrate the overall topology of the 
helical bundle at low resolution, and aid the pinpointing of the four heme iron atoms. These can 
be identified as four sites of strong electron density in the refined 3D model, with inter-heme 
distances that correlate well to the inter-heme distance observed in the 4D2 crystal structure 
and the molecular dynamics simulations of the e4D2 model. 
 
Redox engineering of m4D2. 
The ability to precisely specify and modulate the midpoint potentials of redox sites and cofactors 
within proteins would be an exceptionally valuable tool for protein engineers, and de novo 
designed bundles such as the D2 maquettes provide an invaluable framework for developing 
such a methodology. We therefore selected the monoheme m4D2 for heme redox potential 
modulation, as it is a simple scaffold with potential for manipulating the electrostatic environment 
of the heme. To enable the prediction of heme redox potentials in any planned m4D2 variants, 
we used Monte-Carlo continuum electrostatics (MCCE) calculations16 on static models of our 
proteins, the output providing relative shifts in potential between m4D2 and any altered variants. 
Furthermore, we initially attempted to both raise and lower the redox potential of the heme, thus 
establishing this workflow as a means for redox potential prediction and engineering in these 
proteins. 
 
Previous work with natural peroxidases39,40 has established that aspartate residues local to the 
proximal heme-ligating histidine play key roles in modulating the imidazolate character of the 
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histidine side chain, priming the heme for catalysis by maintenance of the correct histidine 
tautomeric state. This increase in local electronegativity results in a negative shift of the heme 
midpoint potential. For m4D2, we selected the two threonine residues involved in ‘keystone’ 
hydrogen bonding interactions with the proximal histidines for mutation to aspartate, and we 
constructed both single and double mutant variants (T76D & T18D/T76D). The MCCE 
calculations predicted shifts in Em of -27 mV for the single aspartate mutant, and -52 mV for the 
double aspartate mutant (Fig. 9). When we expressed and characterised these designs 
experimentally, shifts of -27 mV and -55 mV respectively were observed at pH 8.6, closely in 
agreement with the values predicted by the MCCE calculations.  
 
Future work will focus on more wholesale remodeling of m4D2 and the multi-heme 4D2 and 
e4D2 proteins to engineer greater changes in the electrostatic environments of these maquettes. 
These calculations can also be incorporated into a pipeline for directed modulation of the 
behavior of these simple proteins and help us to elucidate how the local protein environment 
impacts the behavior of the hemes within them. Significantly, we may be able to engineer 
directional midpoint gradients through multi-heme maquettes, with potential applications in 
electron transport through nanoscale protein-based wires. 
 
Discussion and Conclusions. 
We have attempted to address the deficiencies in high resolution design of de novo redox 
proteins by creating a framework of single and multi-heme proteins with apparently well-defined 
structural attributes. These offer much potential in exploring fundamental biophysical properties 
and functions of cofactors and natural oxidoreductases, such as electron transfer and possibly 
catalysis, while providing stable, robust scaffolds that could play a role in the modular assembly 
of functional nanoscale objects for energy capture and generation. A key feature in design is 
predictability; without this, atomistically precise protein design is not possible, and gaining 
complete and fine control of protein and cofactor properties relies on a potentially exhaustive, 
iterative design process with no guarantee of success. To this end, the structure of 4D2 matches 
well that of the predicted structure of D215, which is a testament to the computational methods 
originally used in the design of the self-assembling peptide. D2 was originally designed by 
parametrization of the transmembrane cytochrome b of the cytochrome bc1 complex, and the 
crystal structure of 4D2 reveals an excellent reproduction of diheme orientation and spacing in 
a robust, mutable and soluble protein.  
 
This scaffold also provides opportunities in the further design and engineering of such proteins. 
Removal of a heme binding site alongside compensatory redesign of the pocket to facilitate 
improved core packing, resulted in a monoheme protein that appears well-folded and retains 
attractive features from the original design. Since 4D2 was essentially cleaved into two separate 
halves for the production of m4D2, it is possible that such proteins can be designed in a modular 
process, where parts with differing biophysical attributes (e.g. redox potentials) can be combined 
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to dictate, for example, the direction of electron transfer along the helical axis, or to create multi-
cofactor proteins with specificity in each individual binding site. This is especially applicable to 
the larger tetraheme e4D2, where directionality could potentially be imparted onto the hemes to 
dictate electron transfer. 
 
By expanding the protein in this way, we were also able to push the current boundary of cryo-
EM41,42,43, principally facilitated by the electron-rich, heme-saturated core. While the data falls 
short of atomistic assignment, it does offer robust evidence of the global protein structure, which 
fits the dimensions of the small, but extended, helical bundle and the hemes located in the core. 
The assembly of the protein requires additional purification after heme loading, but production 
is reliable and the design highly stable, offering a scaffold for the design of properties such as 
directional electron transport through the 8 nm length of the protein.  Our design and modification 
of these derivatives demonstrates the adaptability of the initial 4D2 protein, offering a platform 
for structure-based design and modification from crystal structure to function. 
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Figure 1: The single chain polypeptide 4D2 can be fully assembled with heme by expression in E. coli, although 
heme binding is variable – all four growth conditions in the representative cell pellets pictured (A) are identical but 
were cultured from different colonies from the same transformation. The protein was expressed in all four cultures, 
but minimal heme incorporation is observed from one of the colonies (left). Reliability of heme binding in vivo was 
improved by expression with a periplasmic export tag in the pSHT vector (B) compared to cytoplasmic expression 
in pET151. Mass spectrometry (C) confirms the molecular weight of the apo protein by MALDI (12.63kDa) and the 
assembled two-heme bound holo protein by ESI-MS (13.87 kDa, m/z peaks correspond to Z=5, 2773.02, Z=6 
2208.10, Z=7 1980.85 and Z=8 1733.14). Binding titrations further demonstrate tight binding of heme in a 2:1 ratio.    
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Figure 2: (A) The characteristic absorbance spectra of ligated b-type heme shifts upon reduction from 416nm to 
429nm at the Soret peak alongside the expected splitting of the Q-bands. (B) Redox potentiometry measured using 
an OTTLE (optically transparent thin layer electrochemistry) cell demonstrated reversible reduction of the protein, 
fitted to a 2x1e- Nernst equation to determine the midpoint potential of the two sequential electron transfers. (C) 
Far-UV Circular dichroism spectroscopy indicated the helicity and thermostability of the holo protein, in comparison 
to a relatively unstructured and unstable apo-form. 
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Figure 3: 4D2 formed diffraction quality crystals but growth required up to six months of vapour drop diffusion, 
whilst the two heme-irons enabled experimental phasing by MAD using wavelengths determined by a fluorescence 
edge scan. The structure conforms to D2 symmetry around the ligated heme groups, connected by three loops, two 
of which are sufficiently rigid to be resolved by crystallography. One of the four potential hydrogen bonding 
interactions between the ligating histidine residues and a nearby “keystone” threonine has also been highlighted. 
Ambiguous electron density suggested that the heme groups likely bind in multiple orientations, lacking specificity 
to position the asymmetric vinyl groups. Two of the four potential orientations are illustrated, with the vinyl groups 
either opposing (blue) or adjacent (red) based on a flipping of the porphyrin ring. 
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Figure 4: The crystal structure of 4D2 was used as a starting model to design single-heme and four-heme variants, 
increasing the diversity of subsequent potential design strategies. The sequence and structure of the hydrophobic 
core in the single heme binding m4D2 was redesigned an optimised using a series of simple Rosetta design scripts 
(included in Supplementary Information), and molecular dynamics simulations were used to identify stable, single 
conformation structures in the apo form using RMSD and RMSF (data not shown) analysis of 100 ns trajectories. 
The initial model of e4D2 was designed by building extended coiled-coil structures using ISAMBARD fitted to the 
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Figure 5: Both the single (m4D2) and four heme (e4D2) variants bind the cofactor, resulting in indistinguishable 
absorbance spectra compared to the original protein with an oxidized Soret peak at 416nm and reduced peak at 
429nm. The overall midpoint of e4D2 is equivalent to that of 4D2 (approximately -150 mV) suggesting equivalent 
heme environments within the extended, duplicated structure, whereas the midpoint potential of m4D2 (-118 mV) 
is significantly positively shifted, stabilizing the reduced state of the cofactor. The left panels demonstrate 
representative UV/Visible spectra of the redox titrations, whilst an average of three repeats are depicted on the 
right. 
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Figure 6: Left panel – assembly of the single heme binding m4D2 variant was confirmed by ESI-MS (A), m/z peaks 
of 1500.01 (Z=9), 1687.39 (Z=8) and 1928.30 (Z=9) correspond to the total molecular weight of 13,491.09 Da. Tight 
heme binding and 1:1 stoichiometry was demonstrated by heme titration (B), and homogeneity of the assembly by 
gel filtration (C). The CD spectra of m4D2 demonstrates a high degree of helicity in both the holo and apo forms, 
with stability only marginally disrupted above 80oC observed in the apo state. Right panel – similarly, the fully 
assembly four heme binding e4D2 complex can also be detected by mass spectrometry (Z=9: 2768.17, Z=10: 
2492.03, Z=11: 2265.79, total mass 24,909.24 Da). Addition of heme to the purified apo-e4D2 produced a mixture 
of inhomogeneous aggregates alongside the stable folded complex with the yield improved at increased 
temperature of heme addition (F), however the monomeric form can be separated by gel filtration and remains 
highly stable. The secondary structure of e4D2 is very similar to 4D2 compared to the number of residues (G), 
suggesting successful duplication of the structure. 
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Figure 7: The H1N15-HSQC spectrum of m4D2 is significantly more dispersed than the two heme original design 
4D2, suggesting the single heme protein is also well-structured and further simplified by removal of one of the 
porphyrins. Peak dispersion was further improved by incorporation of the symmetric heme derivative 2,4-dimethyl 
deuteroporphyrin, suggesting that heme binding in two asymmetric orientations resulted in broadening of nearby 
protein signals. The assembly of this cofactor has a slightly blue-shifted absorbance spectra (Soret peaks at 406nm 
and 415nm in the oxidized and reduced forms) and binds slightly less tightly than heme (KD 25 nM vs 3 nM) however 
biophysical properties of the complex are otherwise similar. This well resolved spectra alongside 3D NMR 
experiments enabled comprehensive assignment of peaks (>90%), prediction of secondary structure and torsion 
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Figure 8: (A) Representative 2D class averages (>500 particles per class) from e4D2 cryoEM micrographs 
highlighted the four cofactor binding sites along the length of protein (above), in addition to the arrangement of the 
four helix bundle (below). Initial 3D reconstructions fit closely to the dimensions of the designed protein, and the 
potential position of the iron atoms can be identified at high contrast (C), suggesting slightly helices which are 
slightly less coiled than initially modelled resulting in a longer protein and greater separation between the heme 
groups. This distance matches closely to the equivalent iron-iron distance observed in the crystal structure of 4D2 
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Figure 9: The midpoint potential of the single (T76D) and double (T18D/T76D) threonine mutants of m4D2 
displayed midpoints of –145 mV and –173 mV respectively. These negative shifts in midpoint potential of –27 mV 
for the single mutant and –55 mV for the double mutant were closely aligned to the shifts predicted using MCCE 
calculations of –27 mV for m4D2-T76D and –52 mV for m4D2-T18D/T76D. The left panel shows the reduction 
curves for an average of three experimental repeats fitted with a single-electron Nernst fit, while the right panel 
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Unless indicated, designs were expressed in the cytoplasm within a pET151 vector (Thermo 
Fisher) with an N-terminal 6xHis tag and TEV cleavage sequence. Periplasmic expression was 
utilized to boost non-covalent heme incorporation, facilitated by expression in a modified pMal-
p4x vector (NEB), pSHT18, including an additional N-terminal translocon recognition sequence. 
Gene sequences were synthesized by Eurofins Genomics, and cloned by a Site-Directed 
Ligase Independent Cloning44 method, using Q5 polymerase (NEB) to amplify gene and vector 
sequences prior to hybridization of overhanging fragments. Cloned vectors were transformed 
into Stellar cells (Takara) prior to plasmid purification at a concentration of 30-100 ng/μL using 
an NEB miniprep kit. 
 
Protein Expression and Purification. 
All proteins were expressed in the NEB T7 Express E. coli strain. Transformed colonies were 
cultured overnight in 100 ml LB with carbenicillin at a concentration of 50 μg/ml, and 20 ml of 
culture transferred to 1L of LB which was grown at 37oC to an OD600nm of 0.6 prior to induction 
by addition of 1 mM IPTG. Proteins were expressed for four hours at 37oC, after which cells 
were harvested by centrifugation at 4000xg for 25 minutes and resuspended in lysis buffer (50 
mM Sodium phosphate, 300 mM Sodium chloride, 20 mM imidazole, pH 8). 
 
Isotopically labelled samples for NMR analysis were expressed in minimal media using a 
method adapted from Rupasinghe et al. (2007)45. Proteins were labelled by addition of 15NH4Cl 
(Sigma) alone or in addition to 13C-Glucose (Cambridge Isotopes) for 3D spectra acquisition. 
Cells were grown to an OD600nm of 0.6 as described above prior to centrifugation and washing 
in an M9 salts solution and then resuspended in 250ml minimal media with 15NH4Cl and 4 g/L 
13C-Glucose/Glucose with M9 salts and trace metals. The full composition of the minimal 
media solution was as follows: 18 mM 15NH4Cl, 4g/L glucose, 34 mM Na2HPO4, 22 mM 
KH2PO4, 86 mM NaCl, 2 mM MgCl2, 50 μM FeCl3, 20 μM CaCl2, 10 μM MnCl2,10 μM ZnSO4, 
2 μM CuCl2, 2 μM CoCl2, 2 μM NiCl2, 2 μM H3BO3. Cultures were incubated at 28oC for one 
hour to aid cell recovery before the addition of IPTG, and protein expressed for 16-18 hours at 
28oC. 
 
Resuspended cell-pellets were lysed by four 20-second sonication steps on ice, and cell debris 
removed by centrifugation at 18,000 xg. Designs were initially purified from lysate by nickel 
affinity chromatography (HisTrap column GE), eluting at an imidazole concentration up to 250 
mM. The proteins were immediately dialyzed overnight (SnakeSkin 3.5 kDa MWCO) into a low 
salt buffer optimised for TEV cleavage (50 mM Tris, 0.5 mM EDTA, pH 8), followed by 
cleavage of the N-terminal tags by addition of approximately 200 μg of TEV protease per 3 L of 
culture media and the reducing agent TCEP to a concentration of 1 mM, under anaerobic 
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conditions. Cleaved designs were further purified by reverse nickel chromatography, followed 
by size exclusion chromatography (GE HiLoad 16/600 Superdex 75pg) under final buffer 
conditions of 20mM CHES and 50mM Potassium chloride, pH 8.6. Purified protein samples 
were concentrated using centrifugal concentrators with a molecular weight cut-off of 3 kDa 
(Vivaspin /Amicon). 
 
If necessary, exogenous heme was added in vitro to fully saturate cofactor binding sites by 
dropwise addition of hemin dissolved at 1 mg/ml in DMSO to a small stochiometric excess. 
Excess heme was removed by gel filtration using G25 desalting columns or a further round of 
size exclusion chromatography. Fully apo samples were prepared by acidic butanone 
extraction of the heme cofactor followed by dialysis and gel filtration back into buffer. 
 
Porphyrin Binding Titrations. 
Cofactor binding titrations were carried out by preparation of up to 1000 μL of 2-3 μM apo 
protein solution in a quartz cuvette, followed by incremental addition of porphyrin in low 
volumes of DMSO (0.5-2 μL). Full absorbance spectra between 200-800 nm were measured 
after each addition and thorough mixing. Binding affinity (KD) was calculated by fitting 
absorbance at a single wavelength (the Soret peak) to the tight binding quadratic equation. 
 
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 = [𝐶] × 𝜀!"## + 1𝜀$%&'( − 𝜀!"##3
𝐾) + [𝑃*%*] + [𝐶] − 6(𝐾) + [𝑃*%*] + [𝐶])+ − 4[𝑃*%*][𝐶]
2  
 
[𝐶] = 	Cofactor	Concentration (μM) 
𝜀!"## = 	Unbound	Cofactor	Extinction	Coefficient	(µM-1cm-1) 
𝜀$%&'( = Bound	Cofactor	Extinction	Coefficient	(µM-1cm-1) 
[𝑃*%*] = 	Total	Protein	Concentration	(μM) 
 
Mass Spectrometry. 
The molecular weight of heme bound protein complexes was measured using electrospray 
ionization-mass spectrometry (ESI-MS). Data was acquired using a Waters Xevo G2-XS QTof 
LC-MS instrument – bypassing the liquid chromatography system by direct injection purified 
protein samples at a concentration of 50-200 μM prepared in an aqueous 100mM ammonium 
acetate solution. The sample was injected at a flow rate of 0.25 ml/minute of ammonium 
acetate, with a capillary voltage of 3.6 kV and cone voltage of 50 V, in positive ion mode. 
Predicted ion m/z values were calculated by the following equation, assuming the ionization 
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The molecular weight of apo proteins was validated by Matrix-assisted laser 
desorption/ionization (MALDI) MS, acquired on Bruker UltrafleXtreme equipment. Protein 
samples (concentration approximately 50 μM) were dissolved 1:10 in a matrix solution of 
10mg/ml sinapinic acid in 50:50 water/acetonitrile with 0.1% trifloroacetic acid. 
 
Redox Potentiometry. 
Heme redox potentials were measured by OTTLE potentiometry (Optically transparent thin-
layer electrochemistry) as described previously23. All designed proteins were prepared at a 
concentration of 50 μM in 10% glycerol, 20mM CHES, 100 mM KCl at a pH of 8.6. A total of 
six redox mediators were added at the following concentrations: (Phenazine Ethosulfate 20 
μM, Indigotrisulfonate 50 μM, Duroquinone 6 μM, 2-Hydroxy-1,4-Napthoquinone 25 μM, 
Phenazine 20 μM, Anthroquinone-2-sulfonate 20 μM). UV-visible spectra were measured 
using a Cary 60 spectrophotometer whilst altering the potential via a thin platinum electrode 
between -225 to -525 mV vs a silver chloride electrode, controlled by a Biologic SP-150 
potentiostat. Potentials were adjusted vs the Nernst hydrogen electrode (NHE) by calibration 
with cytochrome C, resulting in an average adjustment of +220 mV. Midpoint potentials (Em) 
were derived by fitting oxidation and reduction data to the following one or two electron Nernst 
equations, where mV is the applied potential and Abs is the absorbance at the reduced Soret 
peak (approximately 429 nm). 
1𝑒!																																	𝐴𝑏𝑠 = (	𝐴 + 𝐵. 10
"#!$!
%& 	- ∕ (	1 + 10
"#!$!
%& 	- 
2 × 1𝑒!																									𝐴𝑏𝑠 = (𝐴. 10
"#!$!"
%& + 𝐶 + 𝐵. 10
"#!$!#







Circular Dichroism (CD) spectra were recorded using a JASCO J-1500 spectrophotometer. All 
protein samples were prepared at a concentration of approximately 5-15 μM, and CD spectra 
baselined against the buffer solution (CHES 20 mM, KCl 100 mM, pH 8.6). CD signal was 
measured at 222 nm whilst changing temperature between 5- 95oC, at a rate of 1oC per 
minute, to track the overall helicity of designs. Full CD spectra were measured between 190-
250 nm at specific temperature points, acquiring eight spectra at each condition and averaging 
the results. Circular dichroism was reported as mean residual ellipticity (MRE) – converting raw 
data by the following equation (where n is the number of peptide bonds in a protein sample):  
𝑀𝑅𝐸	(𝑑𝑒𝑔. 𝑐𝑚'. 𝑑𝑚𝑜𝑙!() =
𝑅𝑎𝑤	𝐸𝑙𝑖𝑝𝑡𝑖𝑐𝑖𝑡𝑦	(𝑚𝑑𝑒𝑔) × 10)
𝑃𝑎𝑡ℎ	𝐿𝑒𝑛𝑔𝑡ℎ	(𝑚𝑚) × 𝑃𝑟𝑜𝑡𝑒𝑖𝑛	𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛	(𝜇𝑀) × 𝑛
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X-Ray Crystallography. 
Crystals suitable for data collection were obtained by the sitting drop vapour diffusion method 
at 22oC using the Morpheus screening conditions (Molecular Dimensions Ltd). Protein samples 
were concentrated to between 10-20 mg/ml and mixed in a 1:1 ratio with precipitant in 1 μl 
sitting drops. X-ray diffraction data were collected at beamline I03 (Diamond Light Source). A 
fluorescence edge scan was measured to determine required wavelengths for phase solving 
by multi-wavelength anomalous dispersion (MAD), collecting diffraction data at peak, inflection 
and high remote wavelengths (1.738 Å, 1.741 Å, 1.698 Å). Diffraction data were integrated and 
scaled with XDS and XSCALE using xia2 prior to phasing and model refinement in the ccp4i246 
software suite. Experimental phasing by MAD was performed using SHELLX, followed by 
iterative model refinement using Refmac5 and Coot. 4D2 crystallized in the H3 space group 
with unit cell dimensions a=81.25 Å, b=81.25 Å and c=59.06 Å. The refined coordinates have 
been deposited to the PDB (ID: 7AH0) and data collection and refinement statistics are 
available in Supplementary Table 1. 
 
NMR. 
Protein samples were concentrated to between 0.5-2 mM in 10% D2O, and NMR spectra were 
obtained with a 700MHz Bruker Avance III HD instrument (BrisSynBio NMR facility). Spectra 
were analyzed using Ccpnmr Analysis7 Version 2.447. 
 
Electron Microscopy. 
Purified protein samples applied to CF300-Cu carbon coated grids (Electron Microscopy 
Sciences) were prepared for negative stain transmission electron microscopy, pre-treating 
grids by glow discharge. Protein concentrations used were between 0.01-0.05 mg/ml, and 
samples were stained with 2% uranyl acetate. 200 images were obtained at magnification 
factors between 50,000- 90,000x, using a Tecnai 20 electron microscope. Individual particles 
were picked, and images processed using Scipion software48 to produce 2D class averages.  
Cryo-electron microscopy micrographs were obtained with a 200kV FEI Talos Arctica (GW4 
CryoEM Facility). Quantfoil R 1.2/1.3 grids were prepared with a protein concentration of 2 
mg/ml. All analysis was completed using Relion 3.049, including motion correction, CTF 
estimation, particle picking and 2D and 3D averaging and model building. 
 
Molecular Dynamics. 
MD trajectories were calculated in AMBER50. The Amber ff14SB forcefield was used to 
parameterize protein residues, whilst parameters derived for the bis-histidine ligated b-type 
heme in Cytochrome C oxidase51 were used for the cofactors. GPU accelerated production MD 
was run using the pmemd.cuda application on University of Bristol HPC clusters (Bluecrystal 
phase 3, 4, BlueGem). Equilibration and molecular dynamics input files and parameters are 
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included in the Supplementary Information. Trajectories were combined and analysed using 
ccptraj. 
Monte-Carlo Continuum Electrostatics (MCCE) 
  
Models of the m4D2 mutants were generated using PyMOL. Structures were solvated and 
energy minimisation performed using GROMACS 5.2.1 with the GROMOS 54a7 force field52. 
Restraints were first set to heavy atoms and then Cα carbon atoms, and finally removed 
entirely. Histidines 36 and 94 were bonded to the heme as part of the redox centre and 
separated from the other titratable sites, and propionate sites were treated as titratable sites. 
The continuum electrostatics-based protonation energies were calculated using the MEAD 
software package, at an ionic strength of 50 mM and a temperature of 300 K. Multiple focused 
grids were constructed, with spacings of 1, 0.5 and 0.25 angstroms respectively. The dielectric 
constant for protein was 20 and for solvent 80. Monte Carlo sampling of protonation states was 
done using the PETIT program. The pH was varied between 8.4 and 8.8 at an interval of 0.2, 
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Supplementary Figure 1: 4D2 1H15N-HSQC spectrum demonstrates moderate peak dispersion, 
insufficient for sequence assignment or further structural analysis. Reconstitution with a symmetric 
porphyrin (right) results in a significant shift, offering further evidence for multiple heme binding states, 
but does not improve the spectrum quality to the same extent as observed for the monoheme variant 
m4D2. 
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Supplementary Figure 2: Quantifying heme binding affinity of e4D2 is challenging due to the mixed 
population of bound states that form upon heme addition. However, negligible transfer of heme to apo-
myoglobin (apoMb) is observed after one hour of mixing at an excess of up to 10-fold myoglobin, 
comparable to heme binding proteins with nanomolar affinity for heme35. Complete transfer of heme to 
myoglobin would result in a 416nm/408nm ratio of 0.77, however only a 1-2% shift of this ratio is detected. 
This further supports tight binding of heme to e4D2. 
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Supplementary Figure 3: Torsion angle predictions from NMR assignments (calculated using DANGLE 
in CCPNMR Analysis) indicate the four ordered helical regions connected by three loops. Deviations at 
residues 20 and 78 are both glycine. 
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Supplementary Figure 4: The HSQC (TROSY experiment) for apo m4D2 confirmed that the protein is 
relatively well structured without bound heme with reasonable peak dispersion, although the repetitive 
sequence is likely to result in significant overlap of signals 
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Supplementary Table 1. Data collection and structural refinement statistics of 4D2 
Data Collection  
Beamline Diamond Light Source, I03 
Wavelength(s) 0.9762, 1.741, 1.738, 1.698 
Space Group H 3 
Unit cell dimensions  
a, b, c (Å) 
𝛼, 𝛽, 𝛾 (°) 
Resolution (Å) 
81.25, 81.25, 59.06 
90, 90, 120 
30.24 - 1.91 (1.960 - 1.91) 
Rmerge (%) 0.129, 1.602 
CC1/2 (%) 99.7 
I/𝜎 (I) 11.1 (1.5) 




Redundancy 9.7 (10.2) 
  
Refinement  
Resolution Range (Å) 30.24 - 1.91 
No. of Reflections 10,644 (796) 
Rwork, Rfree (%) 20.5, 24.4 






Average B factor 43.0 
RMS deviations 
Bond lengths (Å) 





Statistics for the highest-resolution shell are shown in parentheses 
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Supplementary Table 2. NMR chemical shifts for m4D2 (2,4-Dimethyldeuteroporphyrin) 
 
  
H N C CA 
          
3 Pro - - 175.68 65.01 4.37:Ha 1.93:Hba 2.35:Hbb 2.03:Hga 2.09:Hgb 3.83:Hda 3.83:Hdb 31.64:Cb 27.82:Cg 50.92:Cd 
4 Glu 8.54 119.36 176.26 59.18 4.19:Ha 2.11:Hba 2.11:Hbb 2.35:Hga 2.35:Hgb 28.97:Cb 36.89:Cg 
   
5 Leu 8.12 121.95 176.17 57.9 4.13:Ha 1.49:Hba 1.83:Hbb 1.71:Hg 0.91:Hda* 42.50:Cb 26.93:Cg 23.76:Cda 25.15:Cdb 
 
6 Arg 8.26 118.16 175.61 60.44 30.53:Cb 28.89:Cg 43.81:Cd 
       
7 Glu 7.78 118.32 176.34 58.7 4.19:Ha 29.07:Cb 35.99:Cg 
       
8 Lys 8.01 121.24 176.28 59.31 4.15:Ha 32.54:Cb 
        
9 Leu 8.17 118.32 174.95 57.91 3.97:Ha 1.44:Hba 1.84:Hbb 1.14:Hg 0.59:Hda* 0.60:Hdb* 40.90:Cb 27.16:Cda 
  
10 Arg 8.06 118.18 175.64 60.4 3.64:Ha 30.00:Cb 27.35:Cg 43.26:Cd 
      
11 Ala 7.77 120.12 178.19 55.1 4.22:Ha 1.60:Hb* 18.22:Cb 
       
12 Leu 8.13 119.06 176.83 58.12 4.28:Ha 1.45:Hba 1.96:Hbb 1.97:Hg 0.82:Hda* 1.05:Hdb* 43.68:Cb 27.08:Cg 23.31:Cda 26.62:Cdb 
13 Ile 8.63 119.81 175.04 65.54 3.24:Ha 1.50:Hb 0.09:Hg1a 1.16:Hg1b 0.33:Hg2* -0.20:Hd1* 37.23:Cb 30.04:Cg1 17.35:Cg2 13.46:Cd1 
14 Glu 7.72 118.35 177.39 59.9 3.89:Ha 29.05:Cb 36.29:Cg 
       
15 Gln 7.99 117.86 178.17 59.31 4.82:Ha 2.70:Hba 3.01:Hbb 2.83:Hga 3.02:Hgb 30.61:Cb 35.12:Cg 
   
16 Val 9.65 125.27 175.06 68.61 6.31:Ha 2.65:Hb 0.77:Hga* 0.86:Hgb* 31.93:Cb 
     
17 Tyr 8.18 122.35 173.77 61.52 2.08:Hba 2.69:Hbb 38.11:Cb 
       
18 Ala 8.66 121.37 179.32 55.97 3.99:Ha 1.84:Hb* 18.73:Cb 
       
19 Thr 9.5 108.39 175.94 66.65 5.27:Ha 7.11:Hb 2.98:Hg2* 73.81:Cb 24.76:Cg2 
     
20 Gly 9.21 110.62 171.69 44.48 
          
21 Gln 7.09 118.41 176.32 57.66 27.37:Cb 33.07:Cg 
        
22 Glu 7.83 119.25 175.93 59.01 3.77:Ha 29.58:Cb 
        
23 Met 7.04 116.22 174.41 58.11 33.54:Cb 
         
24 Leu 6.42 116.78 174.9 55.67 41.05:Cb 
         
25 Lys 6.87 115.48 173.46 56.85 3.89:Ha 32.93:Cb 
        
26 Asn 7.37 116.94 172.57 52.85 4.71:Ha 2.58:Hba 2.73:Hbb 
       
27 Thr 8.13 112.97 - 63.07 69.02:Cb 21.96:Cg2 
        
28 Ser 7.87 115.79 - 58.05 63.97:Cb 
         
29 Asn 8.43 120.41 - 53.03 39.87:Cb 
         
30 Ser 8.49 117.84 - 57.4 63.36:Cb 
         
31 Pro - - 176.66 65.66 31.87:Cb 27.89:Cg 50.98:Cd 
       
32 Glu 8.7 117.59 177 60.31 4.68:Ha 29.35:Cb 37.00:Cg 
       
33 Leu 8.19 122.79 177.16 58.62 5.14:Ha 2.22:Hba 2.39:Hbb 2.46:Hg 1.41:Hda* 1.66:Hdb* 42.83:Cb 27.86:Cg 24.83:Cda 25.70:Cdb 
34 Arg 8.55 119.65 177.31 61.26 5.34:Ha 30.96:Cb 28.61:Cg 44.17:Cd 
      
35 Glu 8.65 119.06 176.68 59.19 4.85:Ha 29.26:Cb 35.79:Cg 
       
36 Lys 9.06 122.1 178.23 61.06 5.32:Ha 34.01:Cb 3.16:Hba 3.43:Hbb 2.66:Hga 2.54:Hda 3.62:Hea 26.27:Cg 30.36:Cd 42.70:Ce 
37 His 11.26 - 177.73 52.79 33.63:Cb 
         
38 Arg 10.65 120.45 176.3 61.32 30.55:Cb 26.23:Cg 42.93:Cd 
       
39 Ala 9.84 123.06 179.96 56.17 4.45:Ha 2.12:Hb* 18.78:Cb 
       
40 Leu 9.86 120.21 176.97 58.6 4.72:Ha 44.34:Cb 
        
41 Ala 9.72 122.24 177.94 55.42 17.07:Cb 
         
42 Glu 8.56 121.4 176.6 59.74 3.93:Ha 29.15:Cb 35.98:Cg 
       
43 Gln 7.96 119.86 177.42 59.1 4.26:Ha 29.65:Cb 34.66:Cg 
       
44 Val 8.9 123.08 173.44 66.72 3.32:Ha 1.93:Hb 0.40:Hga* 0.72:Hgb* 31.43:Cb 21.67:Cgb 25.43:Cgb 
   
45 Tyr 7.68 120.56 174.75 62.54 3.73:Ha 2.51:Hba 2.79:Hbb 37.98:Cb 
      
46 Ala 7.93 119.19 178.29 55.08 4.04:Ha 1.51:Hb* 18.45:Cb 
       
47 Thr 8.18 115.86 173.05 67.16 3.95:Ha 4.11:Hb 1.16:Hg2* 68.10:Cb 22.19:Cg2 
     
48 Trp 8.58 123.06 173.98 60.05 4.40:Ha 3.14:Hba 3.20:Hbb 29.39:Cb 
      
49 Gln 7.8 113.93 176.36 58.79 3.50:Ha 28.00:Cb 33.75:Cg 
       
50 Glu 7.58 119.75 176.01 59.39 3.93:Ha 29.30:Cb 35.82:Cg 
       
51 Leu 8.06 120.71 176.36 57.99 3.95:Ha 41.87:Cb 25.48:Cda 27.13:Cdb 
      
52 Leu 7.66 117.49 177.54 57.05 3.81:Ha 41.68:Cb 
        
53 Lys 7.75 119.25 175.27 58.7 32.70:Cb 
         
54 Asn 7.9 115.04 173.63 53.34 4.70:Ha 2.90:Hba 2.90:Hbb 39.07:Cb 
      
55 Gly 7.78 107.4 172.17 46 
          
56 Ser 8.28 115.27 171.66 60.11 63.80:Cb 
         
57 Val 7.58 116.44 171.95 61.56 4.20:Ha 1.89:Hb 0.76:Hga* 0.88:Hgb* 33.75:Cb 20.76:Cga 21.80:Cgb 
   
59 Pro - - 173.58 62.62 4.58:Ha 2.01:Hba 2.25:Hbb 1.90:Hga 1.93:Hgb 3.57:Hda 3.65:Hdb 32.02:Cb 27.04:Cg 50.40:Cd 
60 Ser 8.29 116.53 170.66 56.16 4.71:Ha 4.01:Hba 4.16:Hbb 63.03:Cb 
      
61 Pro - - 176.45 65.92 32.13:Cb 27.91:Cg 50.85:Cd 
       
62 Glu 8.69 116.83 176.59 59.93 4.12:Ha 1.96:Hba 2.05:Hbb 2.33:Hga 2.33:Hgb 29.00:Cb 36.66:Cg 
   
63 Leu 7.7 121.41 176.2 57.34 4.25:Ha 1.62:Hba 1.76:Hbb 1.61:Hg 0.89:Hda* 0.95:Hdb* 42.14:Cb 27.31:Cg 24.55:Cda 25.92:Cdb 
64 Arg 8.46 118.74 176.04 60.67 30.65:Cb 28.07:Cg 43.91:Cd 
       
65 Glu 8.06 117.67 176.06 58.55 4.35:Ha 2.12:Hba 2.12:Hbb 2.40:Hga 2.49:Hgb 29.05:Cb 35.93:Cg 
   
66 Lys 7.96 121.27 176.38 59.53 32.89:Cb 
         
67 Phe 8.64 118.39 173.53 61.98 4.04:Ha 2.97:Hba 3.05:Hbb 39.48:Cb 
      
68 Arg 8.26 118.15 175.61 59.98 
          
69 Ala 7.88 119.53 178.33 55.22 18.26:Cb 
         
70 Leu 7.76 119.33 176.28 57.98 42.92:Cb 23.99:Cda 26.09:Cdb 
       
71 Leu 8.45 119.88 176.93 57.7 40.90:Cb 24.46:Cda 26.06:Cdb 
       
72 Glu 8.29 117.23 177.54 59.75 3.98:Ha 29.08:Cb 36.27:Cg 
       
73 Gln 7.95 117.87 178.32 59.47 4.84:Ha 2.76:Hba 3.04:Hbb 2.84:Hga 3.05:Hgb 30.74:Cb 35.30:Cg 
   
74 Val 9.42 125.27 175.23 69.2 6.30:Ha 2.67:Hb 0.78:Hga* 31.99:Cb 22.32:Cga 25.69:Cgb 
    
75 Tyr 7.96 121.17 174.34 62.11 37.40:Cb 
         
76 Ala 8.74 121.87 179.33 55.99 4.06:Ha 1.83:Hb* 18.79:Cb 
       
77 Thr 9.52 108.55 175.96 66.64 5.28:Ha 7.12:Hb 3.00:Hg2* 73.84:Cb 
      
78 Gly 9.04 110.87 172.05 44.27 
          
79 Gln 7.01 118.33 176.26 57.57 27.78:Cb 33.10:Cg 
        
80 Glu 7.77 119.11 175.88 59 29.68:Cb 
         
81 Met 7.03 116.27 174.39 58.11 33.54:Cb 
         
82 Leu 6.41 116.8 174.9 55.67 41.05:Cb 
         
83 Lys 6.87 115.48 173.46 56.85 3.89:Ha 32.93:Cb 
        
84 Asn 7.37 116.94 172.57 52.85 4.71:Ha 2.58:Hba 2.72:Hbb 
       
85 Thr 8.13 112.97 - 63.07 69.02:Cb 21.96:Cg2 
        
86 Ser 7.87 115.79 - 58.05 63.97:Cb 
         
87 Asn 8.43 120.41 - 53.03 39.87:Cb 
         
88 Ser 8.49 117.84 - 57.4 63.36:Cb 
         
89 Pro - - 176.59 65.61 31.83:Cb 27.88:Cg 
        
90 Glu 8.68 117.52 176.96 60.32 4.44:Ha 29.35:Cb 36.97:Cg 
       
91 Leu 8.13 122.89 176.97 58.57 5.11:Ha 42.82:Cb 
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92 Arg 8.47 119.63 177.1 61.17 5.18:Ha 30.93:Cb 28.35:Cg 43.90:Cd 
      
93 Glu 8.6 118.69 176.67 59.17 4.77:Ha 29.26:Cb 
        
94 Lys 8.97 121.99 178.15 61.01 5.29:Ha 
         
95 His 11.22 - - - 
          
96 Arg 10.66 120.47 175.99 61.33 
          
97 Ala 9.74 122.49 180.05 56.14 18.78:Cb 
         
98 Leu 9.8 120.07 176.91 58.54 4.71:Ha 44.29:Cb 
        
99 Ala 9.86 122.38 176.62 55.53 18.07:Cb 
         
100 Glu 8.34 117.15 176.95 59.49 29.18:Cb 36.08:Cg 
        
101 Gln 7.73 118.66 176.94 58.94 4.22:Ha 29.55:Cb 34.70:Cg 
       
102 Val 8.7 122.53 174.43 66.8 3.55:Ha 1.91:Hb 0.38:Hga* 0.60:Hgb* 31.12:Cb 21.43:Cga 24.63:Cgb 
   
103 Ile 7.76 120.11 174.98 64.48 3.68:Ha 1.45:Hb 0.69:Hg1a 0.81:Hg1b 0.44:Hg2* -0.07:Hd1* 36.68:Cb 28.62:Cg1 17.12:Cg2 12.10:Cd1 
104 Ala 7.55 122.09 178.19 55.13 4.09:Ha 1.46:Hb* 18.21:Cb 
       
105 Thr 8.03 114.96 173.45 66.71 4.00:Ha 4.12:Hb 1.10:Hg2* 68.49:Cb 22.07:Cg2 
     
106 Trp 8.66 123.69 174.74 60.27 4.00:Ha 3.05:Hba 3.29:Hbb 28.91:Cb 
      
107 Gln 7.78 113.89 176.2 58.88 3.66:Ha 27.90:Cb 33.94:Cg 
       
108 Glu 7.31 117.6 176.27 58.78 4.00:Ha 29.53:Cb 35.80:Cg 
       
109 Leu 7.89 119.5 175.65 57.57 4.00:Ha 1.32:Hba 1.65:Hbb 1.57:Hg 0.42:Hda* 0.69:Hdb* 42.25:Cb 27.34:Cg 24.58:Cda 25.72:Cdb 
110 Leu 7.45 116.15 174.39 55.09 4.03:Ha 1.31:Hba 1.28:Hg 0.44:Hda* 0.58:Hdb* 41.90:Cb 26.41:Cg 22.83:Cda 25.00:Cdb 
 
111 Lys 7.12 119.38 172.99 57.34 4.11:Ha 33.08:Cb 24.74:Cg 29.54:Cd 42.26:Ce 
     
112 Asn 7.73 124.29 176.68 55.02 4.46:Ha 2.61:Hba 2.75:Hbb 40.76:Cb 
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    <SCOREFXNS> 
     <ScoreFunction name="t14cst" weights="talaris2014_cst" /> 
    </SCOREFXNS> 
    <RESIDUE_SELECTORS> 
    </RESIDUE_SELECTORS> 
    <TASKOPERATIONS> 
            <ReadResfile name="designresidues" filename="resfile.txt"/> 
        <ExtraRotamersGeneric name="extrachi" ex1="1" ex2="1" ex1_sample_level="1" ex2_sample_level="1" /> 
    </TASKOPERATIONS> 
    <FILTERS> 
        <PackStat name="pstat" threshold="0.58" repeats="3"/> 
    </FILTERS> 
    <MOVERS> 
    <ConstraintSetMover name="cst" add_constraints=1 cst_file="constraints.cst"/> 
    <FastDesign name="design" repeats=5 scorefxn="t14cst"  
                clear_designable_residues="false" ramp_down_constraints="false"  
                task_operations="designresidues,extrachi" /> 
    </MOVERS> 
    <APPLY_TO_POSE> 
    </APPLY_TO_POSE> 
    <PROTOCOLS> 
    <Add mover_name="cst"/> 
    <Add mover_name="design"/> 
    <Add filter_name="pstat"/> 
    </PROTOCOLS> 






    <SCOREFXNS> 
        <ScoreFunction name="tlr" weights="talaris2014_cst" /> 
    </SCOREFXNS> 
    <RESIDUE_SELECTORS> 
    </RESIDUE_SELECTORS> 
    <TASKOPERATIONS> 
    <ReadResfile name="resfile" filename="resfile.txt" /> 
    <ExtraRotamersGeneric name="extrachi" ex1="1" ex2="1" ex1_sample_level="1" ex2_sample_level="1" />  
   </TASKOPERATIONS> 
    <FILTERS> 
    <PackStat name="stat1" threshold="0.58" chain="0" repeats="1" /> 
    </FILTERS> 
    <MOVERS> 
    <PackRotamersMover name="pack1" scorefxn="tlr" task_operations="resfile,extrachi"/> 
    <FastRelax name="relax1" /> 
    <ConstraintSetMover name="constraint1" add_constraints="true" cst_file="constraints.cst"/>  
   </MOVERS> 
    <APPLY_TO_POSE> 
    </APPLY_TO_POSE> 
    <PROTOCOLS> 
    <Add mover="constraint1" /> 
    <Add mover="pack1" /> 
    <Add mover="relax1" /> 
    <Add mover="pack1" /> 
    <Add mover="relax1" /> 
    <Add mover="pack1" /> 
    <Add mover="relax1" /> 
    <Add filter="stat1" /> 
    <Add mover="pack1" /> 
    <Add mover="relax1" />   
    </PROTOCOLS> 
    <OUTPUT scorefxn="talaris2014"/> 
</ROSETTASCRIPTS> 
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    <ScoreFunction name="scorewts" weights="score13"> 
        <Reweight scoretype="atom_pair_constraint" weight="1"/> 
        <Reweight scoretype="angle_constraint" weight="1"/> 
        <Reweight scoretype="hack_aro" weight="1"/> 
        <Reweight scoretype="fa_pair" weight="0"/> 
        Reweight scoretype = hack_elec weight = 0.55 
        <Reweight scoretype="rg" weight="2"/> 
    </ScoreFunction> 
    <ScoreFunction name="scorewts_backrub" weights="score13"> 
        <Reweight scoretype="atom_pair_constraint" weight="1"/> 
        <Reweight scoretype="angle_constraint" weight="1"/> 
        <Reweight scoretype="rg" weight="2"/> 
        <Reweight scoretype="hack_aro" weight="1"/> 
    </ScoreFunction> 
    <ScoreFunction name="softwts" weights="soft_rep_design"> 
        <Reweight scoretype="atom_pair_constraint" weight="1"/> 
        <Reweight scoretype="angle_constraint" weight="1"/> 
        <Reweight scoretype="rg" weight="2"/> 
        <Reweight scoretype="hack_aro" weight="1"/> 
    </ScoreFunction> 
</SCOREFXNS> 
<FILTERS> 
    <PackStat name = pstat threshold = 0.58 repeats = 3/> 
</FILTERS> 
<TASKOPERATIONS> 
    <ReadResfile name = rr filename = resfile.txt/> 
    <InitializeFromCommandline name = ifcl/> 
    <IncludeCurrent name = input_sc/> 
    <RestrictToRepacking name = no_mutations/> 
    <ExtraRotamersGeneric name = extra_rot1 ex1 = 1 ex2 = 1 ex1_sample_level = 3 
    ex2_sample_level = 3 extrachi_cutoff = 0/> 
    <OperateOnCertainResidues name = fixpolars> 
        <PreventRepackingRLT/> 
        <ResidueHasProperty property = POLAR/> 
    </OperateOnCertainResidues> 
    <OperateOnCertainResidues name = fixcharged> 
        <PreventRepackingRLT/> 
        <ResidueHasProperty property = CHARGED/> 
    </OperateOnCertainResidues> 
</TASKOPERATIONS> 
<MOVERS> 
    <ConstraintSetMover name = atomic cst_file = constraints.cst/> 
    <PackRotamersMover name = repack scorefxn = scorewts task_operations = ifcl,no_mutations/> 
    <PackRotamersMover name = pr1 scorefxn = softwts task_operations = rr,ifcl/> 
    <PackRotamersMover name = pr2 scorefxn = scorewts task_operations = rr,ifcl,extra_rot1/> 
    <MinMover name=minmovsc scorefxn = softwts tolerance = 0.005 chi=1 bb=0/> 
    <MinMover name=minmovbb scorefxn = scorewts tolerance = 0.005 chi=0 bb=1/> 
    <Backrub name = backrub pivot_residues=1-109 require_mm_bend =1/> 
    <Sidechain name = sidechain task_operations = ifcl,no_mutations,fixpolars,fixcharged/> 
    <ParsedProtocol name = backrub_protocol mode = single_random> 
        <Add mover_name = backrub apply_probability = 0.75/> 
        <Add mover_name = sidechain apply_probability = 0.25/> 
    </ParsedProtocol> 
    <GenericMonteCarlo name = backrub_mc mover_name = backrub_protocol scorefxn_name = 
    scorewts_backrub trials = 200 temperature = 1.2 preapply = 0/> 
    <ParsedProtocol name=flexdes> 
        <Add mover_name=pr1/> 
        <Add mover_name=minmovsc/> 
        <Add mover_name=pr2/> 
        <Add mover_name=minmovbb/> 
        <Add mover_name=pr2 filter_name=pstat/> 
    </ParsedProtocol> 
    <GenericMonteCarlo name=iterate mover_name=flexdes scorefxn_name=scorewts trials=3 






    <Add mover_name=atomic/> 
    <Add mover_name=repack/> 
    <Add mover_name=backrub_mc/> 
    <Add mover_name = iterate/> 
    <Add filter_name = pstat/> 
</PROTOCOLS> 
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Molecular Dynamics Input Files: 
 
Minimization of solvent+Hs with restraints for protein heavy atoms 
&cntrl 
 imin=1, maxcyc=200, ntmin=1,  
 ntpr=10, 
 cut=10.0, 
 ntr=1, restraint_wt=100.0, 
 restraintmask='!:WAT,SOD,CLA & !@H=' 
/  
 
MD heating of solvent with restraints for solute  
&cntrl 
 imin=0, irest=0, ntx=1, 
 nstlim=25000, dt=0.002, 
 ntpr=500, ntwx=5000, ioutfm=1, 
 ntb=2, cut=10.0,  
 ntc=2, ntf=2, 
 ntt=1, tautp=1.0, tempi=50.0, temp0=300.0, 
 ntp=1, taup=1.0, pres0=1.0,   






Minimization of system  
&cntrl 





MD quick heating of system  
&cntrl 
 imin=0, irest=0, ntx=1, ig=-1, 
 nstlim=10000, dt=0.002, 
 ntpr=100, ntwx=5000, ioutfm=1, iwrap=0, 
 ntb=1, cut=10.0, 
 ntc=2, ntf=2, 
 ntt=1, tautp=1.0, tempi=25.0, temp0=300.0, 
/ 
 
200ps NPT MD equilibration of system 
&cntrl 
 imin=0, irest=1, ntx=5, 
 nstlim=100000, dt=0.002, 
 ntpr=1000, ntwx=50000, ioutfm=1, iwrap=0, 
 ntc=2, ntf=2, 
 ntb=2, cut=10.0, 
 ntp=1, pres0=1.0, taup=1.0, 
 ntt=1, tempi=300.0, tautp=1.0,  
/ 
 
10ns NPT MD production simulation 
&cntrl 
 imin=0, irest=1, ntx=5, 
 nstlim=5000000, dt=0.002, 
 ntpr=10000, ntwx=50000, ioutfm=1, iwrap=1, 
 ntc=2, ntf=2, 
 ntb=2, cut=10.0, 
 ntp=1, pres0=1.0, taup=1.0, 
 ntt=1, tempi=300.0, tautp=0.1, 
/ 
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